Special Issue "Infectious Complications in Patients with Hematologic Malignancies and Allogeneic Stem Cell Transplant Recipients"
A special issue of Hemato (ISSN 2673-6357).
Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 4390
Interests: stem cell transplantation; cellular therapies; CART cells; infectious complications
Interests: allogeneic hematopoietic stem cell transplantation (HSCT); conditioning regimens; GVHD; regimen-related toxicity; MDS and AML; chronic myeloproliferative disorders; opportunistric infections in onco-hematology; supportive care in onco-hematology and HSCT; administrative support in HSCTY, including JACIE
Over the last 10 to 15 years, the treatment options for patients with hematologic malignancies have seen the blossom of a large number of new agents and new therapeutic strategies like cellular therapies.
Despite achieving remarkable improvements in the management of patients with malignant hematologic disorders, infectious complications still represent a leading cause of morbidity and mortality, thereby limiting the effectiveness of curative strategies.
In this respect, knowledge of the epidemiology and risk factors of infectious complications as well as of the available therapeutic armamentarium may represent a tool of paramount importance to optimize the treatment of hematologic patients.
The aim of this Special Issue is to summarize the current data on bacterial, fungal, and viral infections in hematologic patients, providing the reader with a guide to design an appropriate therapeutic approach to the prophylaxis and treatment of infectious complications.
Dr. Alessandro Busca
Dr. Rodrigo Martino
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hemato is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.